LivaNova PLC

LivaNova PLC held its 2026 Annual General Meeting on June 10, 2026, where shareholders adopted all 10 proposed resolutions. Key approvals included the election of eleven directors for a term expiring at the 2027 AGM, and the advisory approval of the company's named executive officers' compensation. Shareholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 and authorized directors to allot shares and equity securities for cash.

LivaNova PLC reported a net income of $22.29 million for Q1 2026, a significant improvement from a net loss of $327.32 million in Q1 2025, primarily due to the absence of a large SNIA environmental liability expense. Revenue increased to $362.26 million from $316.86 million year-over-year. The company also made an early repayment of $95.9 million on its Term Facilities and achieved a key regulatory milestone for its ImThera acquisition.

LivaNova PLC reported strong first-quarter 2026 financial results, with revenue increasing 14.3% to $362.3 million and adjusted diluted EPS reaching $0.98. The company also raised its full-year 2026 revenue growth guidance to 7.0%-8.0% and adjusted diluted EPS guidance to $4.20-$4.30. Additionally, LivaNova received U.S. FDA premarket approval for its aura6000 System for moderate to severe obstructive sleep apnea, marking a significant regulatory and clinical milestone. The company will host a business update conference call today, May 6, 2026.

LivaNova PLC announced its 2026 Annual General Meeting (AGM) will be held virtually on June 10, 2026. Shareholders of record as of April 13, 2026, are eligible to vote on ten proposed resolutions, including the election of 11 directors, advisory votes on executive and UK directors' remuneration, and the re-appointment of auditors. Key proposals also include granting authority to allot shares and approve share repurchase contracts.